Gainers

• IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million.
• Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 41.87% to $2.27. The market value of their outstanding shares is at $4.0 million.
• DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 25.64% to $5.83. The market value of their outstanding shares is at $14.8 million.
• Akanda (NASDAQ:AKAN) stock increased by 13.26% to $3.33. The market value of their outstanding shares is at $1.5 million.
• Pluri (NASDAQ:PLUR) shares moved upwards by 12.96% to $1.22. The market value of their outstanding shares is at $13.3 million.
• Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 11.48% to $0.87. The market value of their outstanding shares is at $149.0 million.

Losers

• Xenon Pharmaceuticals (NASDAQ:XENE) shares declined by 23.3% to $44.0 during Friday's pre-market session. The company's market cap stands at $5.5 billion.
• OraSure Technologies (NASDAQ:OSUR) shares fell 14.05% to $3.0. The market value of their outstanding shares is at $240.7 million.
• Firefly Neuroscience (NASDAQ:AIFF) shares declined by 10.94% to $1.14. The market value of their outstanding shares is at $20.0 million.
• Nuwellis (NASDAQ:NUWE) stock decreased by 10.56% to $0.97. The market value of their outstanding shares is at $3.4 million.
• CDT Equity (NASDAQ:CDT) shares fell 10.56% to $0.17. The company's market cap stands at $2.5 million.
• Aethlon Medical (NASDAQ:AEMD) shares fell 9.55% to $6.13. The company's market cap stands at $4.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.